Vulvovaginal candidiasis: evolution of a therapeutic approachs
Keywords:vulvovaginal candidiasis, fungi Candida, butoconazole, technology VagiSite, biofilm, Gynofort
Vulvovaginal candidiasis – one of the most common causes of vaginitis symptoms among women of reproductive age: 75% of women faced with this disease at least once in their lives. Fungi Candida is well known cause of vulvovaginal candidiasis. 85–95% of all strains of yeasts isolated from patients with vaginal candidiasis belong to Candida albicans. It is proved butoconazole that has a high efficacy in eradicating fungi Candida and high speed relief of symptoms. A bioadhesive technology VagiSite (emulsion “water in oil”), used in the preparation of a 2% butoconazole nitrate Gynofort allows butoconazole permanently retained on wet vaginal mucous, slowly releasing
- Sobel, J. D. “Vulvovaginal candidosis.” Lancet, 9577(2007) (Vol. 369): 1961–1971.
- E ckert, L.O., Hawes, S.E., Stevens, C.E., Koutsky, L.A., et al. “Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm.” Obstet Gynecol, 5(92) (1998): 757–765.
- O dds, F.C., Webster, C.E., Mayuranathan, P., Simmons, P.D. “Candida concentrations in the vagina and their association with signs and symptoms of vaginal candidosis.” J Med Vet Mycol, 5(26) (1988): 277–283.
- Landers, D.V., Wiesenfeld, H.C., Heine, R.P., Krohn, M.A., Hillier, S.L. “Predictive value of the clinical diagnosis of lower genital tract infection in women.” Am J Obstet Gynecol, 4(190) (2004): 1004–1010.
- N yirjesy, P., Alexander, A.B., Weitz, M.V. “Vaginal Candida parapsilosis: pathogen or bystander?” Infect Dis Obstet Gynecol, 1(13) (2005): 37–41.
- Soloviova, A.V., Plaksina, N.D., Silvestrova, G.A. “Vulvovaginal candidiasis: how to avoid recurrence.” Female doctor, 2(52) (2014): 49–55.
- Beigi, R.H., Meyn, L.A., Moore, D.M., Krohn, M.A., Hillier, S.L. “Vaginal yeast colonization in non-pregnant women: a longitudinal study.” Obstet Gynecol, 5(104) (2004): 926–930.
- Geiger, A.M., Foxman, B. “Risk factors for vulvovaginal candidiasis: a case-control study among university students.” Epidemiology, 2(7) (1996): 182–187.
- C haim, W., Foxman, B., Sobel, J.D. “Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype.” J Infect Dis, 3(176) (1997): 828–830.
- C otch, M.F., Hillier, S.L., Gibbs, R.S., Eschenbach, D.A. “Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. Vaginal Infections and Prematurity Study Group.” Am J Obstet Gynecol, 2(178) (1998): 374–380.
- D ennerstein, G.J., Ellis, D.H. “Oestrogen, glycogen and vaginal candidiasis.” Aust N Z J Obstet Gynaecol, 3(41) (2001): 326–328.
- T arry, W., Fisher, M., Shen, S., Mawhinney, M. “Candida albicans: the estrogen target for vaginal colonization.” J Surg Res, 2(129) (2005): 278–282.
- Foxman, B. “The epidemiology of vulvovaginal candidiasis: risk factors.” Am J Public Health, 3(80) (1990): 329–331.
- M ahmoudi Rad, M., Zafarghandi, S., Abbasabadi, B., Tavallaee M. “The epidemiology of Candida species associated with vulvovaginal candidiasis in an Iranian patient population.” Eur J Obstet Gynecol Reprod Biol, 2(155) (2011): 199–203.
- Fidel, P.L. Jr., Vazquez, J. A., Sobel, J.D. “Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.” Clin Microbiol Rev, 1(12) (1999): 80–96.
- D e Leon, E.M., Jacober, S.J., Sobel, J.D., Foxman, B. “Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes.” BMC Infect Dis, 2(2002): 1.
- Goswami, R., Dadhwal, V., Tejaswi, S., Datta, K., Paul, A., et al. “Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status.” J Infect, 2(41) (2000): 162–166.
- D onders, G.G., Prenen, H., Verbeke, G., Reybrouck R. “Impaired tolerance for glucose in women with recurrent vaginal candidiasis.” Am J Obstet Gynecol, 4(187) (2002): 989–993.
- Spinillo, A., Capuzzo, E., Acciano, S., De Santolo, A., Zara, F. “Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis.” Am J Obstet Gynecol, 1(180) Pt. 1 (1999): 14–7.
- W ilton, L., Kollarova, M., Heeley, E., Shakir S. “Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England.” Drug Saf, 8(26) (2003): 589–597.
- P irotta, M.V., Gunn, J.M., Chondros, P. “"Not thrush again!" Women's experience of post-antibiotic vulvovaginitis.” Med J Aust, 1(179) (2003): 43–46.
- Bluestein, D., Rutledge, C., Lumsden, L. “Predicting the occurrence of antibiotic-induced candidal vaginitis (AICV).” Fam Pract Res J, 3(11) (1991): 319–326.
- P ultz, N.J., Stiefel, U., Ghannoum, M., Helfand, M.S., Donskey, C.J. “Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice.” Antimicrob Agents Chemother, 1(49) (2005): 438–440.
- Bradshaw, C.S., Morton, A.N., Garland, S.M., Morris, M. B., et al. “Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis.” Obstet Gynecol, 1(106) (2005): 105–114.
- R eed, B.D., Zazove, P., Pierson, C.L., Gorenflo, D.W., Horrocks, J. “Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis.” J Womens Health (Larchmt), 10(12) (2003): 979–989.
- Sobel, J. D. “Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis.” Am J Obstet Gynecol, 7(152) Pt. 2 (1985): 924–935.
- M iles, M.R., Olsen, L., Rogers, A. “Recurrent vaginal candidiasis. Importance of an intestinal reservoir.” JAMA , 17(238) (1977): 1836–1837.
- C hong, P.P., Lee, Y.L., Tan, B.C., Ng, K.P. “Genetic relatedness of Candida strains isolated from women with vaginal candidiasis in Malaysia.” J Med Microbiol, 8(52) (2003): 657–666.
- Garcia-Tamayo, J., Castillo, G., Martinez, A.J. “Human genital candidiasis: histochemistry, scanning and transmission electron microscopy.” Acta Cytol, 1(26) (1982): 7–14.
- King, R.D., Lee, J.C., Morris, A.L. “Adherence of Candida albicans and other Candida species to mucosal epithelial cells.” Infect Immun, 2(27) (1980): 667–674.
- Bertholf, M.E., Stafford, M.J. “Colonization of Candida albicans in vagina, rectum, and mouth.” J Fam Pract, 5(16) (1983): 919–924.
- A l-Hedaithy, S.S. “Spectrum and proteinase production of yeasts causing vaginitis in Saudi Arabian women.” Med Sci Monit, 7(8) (2002): 498–501.
- Zarnowski, R., Westler, W.M., Lacmbouh, G.A., Marita, J. M., Bothe J. R., et al. “Novel entries in a fungal biofilm matrix encyclopedia.” MBio, 4(5) (2014): e01333–14.
- Seidman, L.S., Skokos, C.K. “An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis.” Infect Dis Obstet Gynecol, 4(13) (2005): 197–206.
- Van Heusden, A.M., Merkus, H.M., Euser, R., Verhoeff, A. “A randomized, comparative study of a single oral dose of fluconazole versus a single topical dose of clotrimazole in the treatment of vaginal candidosis among general practitioners and gynaecologists.” Eur J Obstet Gynecol Reprod Biol, 2(55) (1994): 123–127.
- Brown, D., Henzl, M.R., Kaufman, R.H. “Butoconazole nitrate 2% for vulvovaginal candidiasis. New, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. Gynazole 1 Study Group.” J Reprod Med, 11(44) (1999): 933–938.
- E xpert Board of Polish Gynecological Society “The statement of Polish Gynecological Society Experts on the treatment of acute vulvovaginal candidiasis with prolonged releasing 2% butoconazole nitrate vaginal cream--state of art in 2008.” Ginekol Pol, 4(80) (2009): 303–311.
- Thompson, D., Saul Levinson, R. “The bioadhesive system of local drug administration.” Women's Health, 3(27) (2006): 1–4.
How to Cite
Copyright (c) 2015 М. В. Медведев
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.